Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Bortezomib + Dexamethasone + Ricolinostat|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bortezomib||Velcade||Velcade (bortezomib) is a reversible proteasome inhibitor that inhibits survival of malignant cells and regulates bone remodeling (PMID: 26579531). Velcade (bortezomib) is FDA approved for the treatment of mantle cell lymphoma and multiple myeloma (FDA.gov).|
|Ricolinostat||ACY-1215||HDAC Inhibitor 38||Ricolinostat (ACY-1215) is a selective inhibitor of HDAC6, which may decrease tumor cell viability and reduce tumor growth, alone or in combination with other agents (PMID: 22262760, PMID: 27926524, PMID: 32705192).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||multiple myeloma||not applicable||Bortezomib + Dexamethasone + Ricolinostat||Phase Ib/II||Actionable||In a Phase Ib/II trial, the Phase II recommended dose of Ricolinostat (ACY-1215) combined with Velcade (bortezomib) and Adexone (dexamethasone) resulted in safety and tolerance, and an overall response rate of 37% in patients with multiple myeloma (PMID: 28053023).||28053023|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|